Get the Stockscreener App
1.0001
0.00%
0.0099
Marker Therapeutics Inc stock is traded at $1.0001, with a volume of 116.08K.
It is up +0.00% in the last 24 hours and up +5.80% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
116.08K
Relative Volume:
0.06
Market Cap:
$13.07M
Revenue:
-
Net Income/Loss:
$-9.70M
P/E Ratio:
-0.9092
EPS:
-1.1
Net Cash Flow:
$-8.57M
1W Performance:
-6.48%
1M Performance:
+5.80%
6M Performance:
-1.94%
1Y Performance:
-62.73%
1-Day Range:
$0.97
$1.025
1-Week Range:
$0.97
$1.13
52-Week Range:
$0.8099
$5.95
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.0099 | 13.07M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.52 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Is this a good reentry point in Marker Therapeutics Inc.Weekly Market Outlook & Low Risk High Win Rate Stock Picks - newser.com
Does Marker Therapeutics Inc. show high probability of reboundTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Using R and stats models for Marker Therapeutics Inc. forecasting2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Tools to assess Marker Therapeutics Inc.’s risk profileMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Developing predictive dashboards with Marker Therapeutics Inc. dataJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
What valuation multiples suggest for Marker Therapeutics Inc. stockPortfolio Update Report & Advanced Swing Trade Entry Alerts - newser.com
Marker Therapeutics Inc. stock retracement – recovery analysisQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Volatility clustering patterns for Marker Therapeutics Inc.Dip Buying & Fast Gain Stock Tips - newser.com
Why retail investors pile into Marker Therapeutics Inc. stock2025 Top Gainers & High Win Rate Trade Tips - newser.com
Marker Therapeutics Inc. stock daily chart insightsAnalyst Downgrade & Entry Point Confirmation Signals - newser.com
Real time breakdown of Marker Therapeutics Inc. stock performanceJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Best data tools to analyze Marker Therapeutics Inc. stock2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
What makes Marker Therapeutics Inc. (GX1) stock appealing to growth investorsJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - Sahm
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment - TipRanks
Marker Therapeutics Launches Phase 1 RAPID Trial for Multi-Antigen Recognizing T Cells as Off-the-Shelf Treatment for AML and MDS - Quiver Quantitative
100x10^6‑cell initial dose: Marker Therapeutics treats first patient with MT‑401 in Phase 1 OTS RAPID study - Stock Titan
Marker Therapeutics Inc GX1 Stock Analysis and ForecastSwing Trading Watchlist & Exceptional Capital Trading - earlytimes.in
Is Marker Therapeutics Inc. trending in predictive chart models2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Will Marker Therapeutics Inc. stock maintain momentum in 2025Quarterly Portfolio Summary & Daily Entry Point Alerts - newser.com
How forex fluctuations impact Marker Therapeutics Inc. (GX1) stockMarket Risk Report & AI Enhanced Execution Alerts - newser.com
Will Marker Therapeutics Inc. (GX1) stock split increase liquidity2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Is Marker Therapeutics Inc. (GX1) stock worth holding before Fed meeting2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Is Marker Therapeutics Inc. (GX1) stock prepared for digital transition2025 Short Interest & Real-Time Volume Trigger Notifications - newser.com
Visualizing Marker Therapeutics Inc. stock with heatmapsJuly 2025 Levels & Reliable Entry Point Alerts - newser.com
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marker Therapeutics Inc Stock (MRKR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
0.11%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):